Problems in development of Halfkine Institute for Training Research and Testing

2202. SHRI SURESH KALMADI: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Government are facing problems to develop Halfkine Institute for Training, Research and Testing and Halfkine Bio-pharmaceutical Corporation Ltd. with the help of Russian technology; and

(b) what action Government propose to take in the matter?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) and (b) The information is being collected and will be laid on the Table of the House.

Clearance for Marketing of Ethyloestrenol, Methandienone and Stanozolol

2203. SHRI P. N. SUKUL: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Ethyloestrenol, Methandienone and Stanozolol have been cleared for marketing in the country;

(b) if so, when were these drugs cleared and what are the details of indications for which each is used;

(c) whether any precaution is to be taken for any of these drugs;

(d) what are the counter indications of each drug;

(e) whether any of these drugs have hazard effect;

(f) if so, the details thereof;

(g) what are the details of corrective steps in that regard; and

(h) what was the quantity of each drug imported in the country during the last two years along with names of importers, quantity imported by each, CIF price per kg. and source of import?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Yes, Sir.

(b) The enabolic steroids Methandienone, Stanozolol, Ethylestrenol which are indicated for chronic debilitating diseases particularly in old age, osteoporosis, refractary and aplastic anaemia selected cases of prepubertal growth retardation were cleared for marketing in February, 1963, June, 1965 and June, 1962 respectively.

(c) to (f) Precautions side effects and contraindications for these drugs are at Statement-I.

(g) Precautions to be observed while prescribing anabolic steroids are given in Statement-I.

(h) As per information available with this Ministry the quantity of each drug imported during the last two years along with the C.I.F. value is at Statement-II.

Statement-I

Precautions

1. Anabolic Steroids should be administered only intermittently not exceeding three months at a time. If no beneficial effect is observed during this period, the drug should be discontinued. The interval between two cources of treatment should not be less than 3 months.

2. While using Anabolic steroids in the pre-pubertal age group, there